GSK (LON:GSK – Get Free Report)‘s stock had its “hold” rating reissued by research analysts at Deutsche Bank Aktiengesellschaft in a report issued on Tuesday, Digital Look reports. They currently have a GBX 2,000 target price on the stock. Deutsche Bank Aktiengesellschaft’s price target indicates a potential upside of 12.04% from the stock’s current price.
Other analysts have also recently issued reports about the stock. Berenberg Bank upped their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 1,975 target price on shares of GSK in a report on Tuesday, September 8th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of GBX 2,064.38.
Get Our Latest Stock Analysis on GSK
GSK Stock Down 0.6%
GSK (LON:GSK – Get Free Report) last announced its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Equities research analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.
Insider Buying and Selling at GSK
In other news, insider Anne Beal bought 637 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was bought at an average price of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds purchased 1,500 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were purchased at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Insiders bought a total of 2,144 shares of company stock valued at $6,009,566 over the last three months. Insiders own 0.20% of the company’s stock.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
See Also
- Five stocks we like better than GSK
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
